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Prostate cancer is the second most diagnosed solid-organ 
malignancy in men1, with >1.2 million new cases and 
358,989 deaths reported worldwide in 2018 (ref.2). Since 
2005, the global men’s health charity Movember has 
invested in a variety of very influential programmes in 
biomedical research, survivorship and clinical quality and 
has set ambitious organizational objectives to work with its 
global partners to halve the number of deaths from pros-
tate cancer and to halve the number of men facing ongo-
ing adverse effects from treatment by 2030. In order to 
transform these aspirations into reality, Movember needs 
to understand the gaps and opportunities in the field.
Given that the last published analysis of the field 
was conducted by Tindall and Scardino3 ~20 years ago, 
Movember’s Global Scientific Committee (GSC) recom-
mended that the Movember Biomedical Research Team 
commission a formal landscape analysis to assess the 
international prostate cancer research field in order 
to optimize future research investment and maximize 
biomedical research outcomes. The scope of this analy-
sis was restricted to the role of Movember as a funder 
whose purpose is to positively change clinical practice 
in the prostate cancer biomedical research field for the 
benefit of men.
In this Consensus Statement, we present the results 
and conclusions of Movember’s prostate cancer global 
landscape analysis.
Methods
The Movember prostate cancer landscape analysis 
commenced in April 2017. A sequential research design 
was used, in which insights gathered from stakeholder 
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interviews were collated, prioritized and discussed dur-
ing a facilitator-led expert workshop for consensus in 
December 2017 (fig. 1). First, men with prostate cancer 
were invited to provide their personal experience and 
reflections via in-depth interviews with members of 
the Movember Biomedical Research Team (M.B. and 
M.M.K.). A diverse range of thought leaders were also 
interviewed to gauge their views on the current state of 
prostate cancer research, funding climate and the opti-
mal role for Movember in the global research landscape. 
Interview responses were collated and analysed to cre-
ate a list of insights ranked by response frequency. An 
expert Landscape Analysis Committee (LAC) was con-
vened in order to evaluate the highest-ranked insights 
against research prioritization criteria, which were based 
on LAC consensus and were defined and explained to 
the LAC workshop participants in advance. In total, 
five thematic areas were considered for prioritization: 
health outcomes, research significance, implementation, 
equity and the state of current research (Table 1). Insights 
were subsequently ranked as research needs. Process 
design and workshop facilitation was supported by an 
independent systems research consultant (S.L.D.).
Benchmarking other landscape analyses
In total, three highly relevant landscape analyses were 
benchmarked — Tindall and Scardino’s original prostate 
cancer landscape analysis3, the Metastatic Breast Cancer 
Landscape Analysis research report from the Metastatic 
Breast Cancer Alliance4 and the Cancer Moonshot Blue 
Ribbon Report5 — to understand the methodological 
approaches that were used, garner key lessons learned 
and adopt best practice. The approaches were revie wed and 
adapted to reflect Movember’s role as a backbone organi-
zation as part of a collective impact model in the broader 
prostate cancer biomedical research setting6,7.
Stakeholder interviews
M.M.K. and M.B. conducted a total of 53 in-depth 
one-on-one interviews with men with prostate cancer 
(n = 9) and global thought leaders in the field of pros-
tate cancer research (n = 44) to gather a broad range of 
insights to be used as context and content for the LAC 
workshop (box 1). Using a modified human-centred 
approach, nine men from Australia, the USA and Europe 
with disease ranging from localized with no progression 
after primary treatment to advanced metastatic, shared 
their personal experiences of living with prostate cancer, 
including diagnosis, treatment and support received in 
both clinical and survivorship care, awareness of clini-
cal trials available and the most considerable challenges 
and/or barriers. The interviews with the men with pros-
tate cancer also included standardized questions and 
queries about gaps or roadblocks that prevent advances 
in the prostate cancer research space and how they could 
be addressed from a patient’s perspective, aspects of bio-
medical prostate cancer research that Movember should 
invest in that would have helped with their own experi-
ences with prostate cancer, and what success would look 
like if the endeavour were to be successful. Additionally, 
44 thought leaders from a broad range of relevant dis-
ciplines (including health economists, epidemiologists, 
urologists, medical oncologists, radiation oncologists, 
pathologists, foundation and health organization repre-
sentatives, research academics and industry representa-
tives) were invited to provide their professional opinion 
in response to a list of standardized questions, which 
included queries about the future of prostate cancer 
research and health care over the next 3–5 years; where 
there is existing momentum; the research gaps that need 
addressing to move the field forwards; where Movember 
should invest over the next 3–5 years to have the great-
est influence; how Movember can best coordinate a col-
lective approach to consolidate the field and maximize 
patient outcomes; where other funders are investing in 
the space and the current barriers to conducting clinical 
trials in prostate cancer (box 2).
Standardized questions were developed by bench-
marking and reviewing earlier landscape analyses3–5 
and direct discussions with the programme leaders 
who conducted previous prostate cancer and Metastatic 
Breast Cancer Landscape analyses4. The questions were 
Author addresses
1Movember, Melbourne, victoria, australia.
2the systems school, Melbourne, victoria, australia.
3Center for Cancer research, National institute of Health/National Cancer institute, 
Bethesda, MD, usa.
4swOG Cancer research Network, Prostate Cancer Patient advocate, Portland, Or, usa.
5Patrick G Johnston Centre for Cancer research, Queen’s university Belfast, Belfast, uK.
6Department of urology, erasmus Medical Center, rotterdam, Netherlands.
7university of utah, salt Lake City, ut, usa.
8alfred Health radiation Oncology, the alfred Hospital school of science, Melbourne, 
victoria, australia.
9rMit university, Melbourne, victoria, australia.
10sunnybrook research institute, sunnybrook Health science Centre, university of 
toronto, toronto, Ontario, Canada.
11university of Minnesota, Minneapolis, MN, usa.
12université Catholique de Louvain, Louvain-la-Neuve, Belgium.
13european Organisation for research and treatment of Cancer, Brussels, Belgium.
44 thought leaders and 9 men with 
prostate cancer
LAC workshop
4 × Movember considerations
5 × prioritization criteria
7 × disease stages
Interview insights were consolidated to 
create 67 key insights, which were ranked
based on the number of times they were 
mentioned at the interviews
• Low priority — <4 mentions
• High priority — ≥4 mentions
High priority key insights = research needs
67 ranked key insights
Key insights with 4 or more mentions
12 research needs
Nominated by the LAC
Qualitative analysis of interviews
53 stakeholder interviews
17 ranked research needs
5 additional research needs+
Fig. 1 | overview of the landscape analysis process. The landscape analysis 
methodology involved one-to-one interviews, qualitative analysis and consultation with 
international experts (the Landscape Analysis Committee (LAC)). The research needs 
were then ranked using agreed prioritization criteria at the LAC workshop meeting.
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reviewed and endorsed by the Movember GSC, which 
comprises global thought leaders in prostate cancer 
research.
At the commencement of all interviews, an outline 
of Movember’s role as a not-for-profit organization with 
limited resources to maximize patient outcomes was 
provided for context.
Upon completion of the interviews, all responses 
were analysed qualitatively and consolidated using 
a thematic approach to generate a list of key insights 
ranked by the response frequency (the number of times 
the insight was mentioned by the interviewees). For the 
purposes of generating a shortlist of research needs, only 
those key insights mentioned by four or more interview-
ees were prioritized for discussion at the LAC workshop 
(n = 12; referred to as ‘research needs’ hereafter). The 
members of the LAC were asked to draw on their own 
expertise and collectively determined that the shortlisted 
12 research needs were not entirely sufficient to describe 
all of the critical unmet research needs in the field. Thus, 
the LAC reviewed all 67 insights gathered from the inter-
views and, based on a consensus approach, determined 
that one lower-ranked insight (in terms of the number 
of times mentioned) should also be included for prioriti-
zation review. Four additional research needs were nomi-
nated and agreed by the LAC. All 17 (12 + 5) were revie wed 
and agreed upon amongst all LAC members before 
the face-to-face workshop.
Landscape Analysis Committee
Towards the end of the interview process, a LAC 
comprising global thought leaders was assembled by 
Movember. The aim was for the committee to meet 
face-to-face as an expert group to review the key insights 
and research needs identified from the stakeholder inter-
views in the context of agreed research prioritization 
criteria. Representation of the following disciplines was 
deemed crucial: urology, medical oncology, radiation 
oncology, radiology, pathology, academic translational 
research, health economics and research implementa-
tion, and patient advocacy. Members of the LAC were 
considered to be thought leaders in their field and a 
balance was sought between discipline, geographical 
region and gender. A focus of the landscape analysis was 
prostate cancer biomedical research, but several LAC 
members also had strong expertise in prostate cancer 
clinical quality and/or patient survivorship.
The composition of the final LAC was Bertrand 
Tombal (urology, Belgium), Charles J. Ryan (medical 
oncology, USA), Beatrice S. Knudsen (pathology, USA), 
Suneil Jain (clinical oncology, UK), Jeremy L. Millar 
(radiation oncology, Australia), Peter L. Choyke (radiol-
ogy, USA), Guido W. Jenster (translational research, 
Netherlands), Nicole Mittmann (health economics and 
policy, Canada), Tony Crispino (patient advocacy, USA) 
(box 1).
A face-to-face workshop facilitated by a systems 
research consultant (S.L.D) was held in Los Angeles 
in December 2017, with the aim of interrogating the 
identified research needs in the context of a set of 
agreed research prioritization criteria (Table 1) and rank 
the research needs for future consideration of Movember 
funding. These prioritization criteria included the ability 
to improve patient quality of life (QOL), reduce the bur-
den of disease, be implementable, address health inequi-
ties, and have significant current momentum, and were 
agreed via a consensus process before the face-to-face 
workshop. Each prioritization criterion (which considers 
the broad context outside of biomedical research) was 
applied equally to all identified research needs through 
multiple rounds of group discussion at the workshop.
Establishing prioritization criteria
As part of the quality assurance process and to establish 
appropriate research prioritization criteria that would 
enable identification of the most pressing research needs 
requiring potential future research investment, a review of 
the literature on research prioritization criteria and pro-
cesses was conducted in order to benchmark best prac-
tice. The review was conducted in Scopus in mid-2017 
and terms included ‘criteria’ AND ‘health’ AND ‘priority/
priorities’ AND ‘investment’. From the 125 publications 
returned using the search terms, a review of the abstracts 
for appropriateness identified 16 publications of relevance. 
Table 1 | research prioritization criteria
Thematic area Criteria Definition refs
Health outcomes Improved patient 
QOL
The research has the potential to improve the QOL of a patient 
within a specific step of the treatment journey and/or improved 
QOL during and beyond the treatment process
8
Research significance Reduces burden of 
disease
The research has the potential to markedly reduce the burden 
of disease. Research needs to be important, innovative, 
non-redundant and address a key research gap
9,12
Implementation Implementable The barriers to implementation are not insurmountable 
(the research is technically and practically feasible), and 
the research has the potential to move to the next stage of 
development (is translational or clinical)
8
Equity, ethics, fairness Health inequities The research has the potential to positively impact and be 
accessible to a diverse range of men across a diverse range of 
geographies
10,11
State of current research Significant current 
momentum
Research in the field that could enable significant improvement 
in the research need, if Movember were to support it
NA
NA, not applicable; QOL, quality of life.
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Five publications were ultimately deemed to be the most 
relevant to the needs of men with prostate cancer8–12.
Two approaches were identified regarding how to 
develop the prioritization criteria. In a systematic review 
of multi-criteria decision analyses, Cromwell et al.13 
identified a set of common domains that were used to 
group decision-making criteria. A review of the CHNRI 
method for setting health research priorities suggested 
prioritization based on the 4D method (description, 
delivery, development, discovery), whereby potential 
research avenues are first categorized by type of research 
instrument and the decision-making criteria are applied 
directly to the proposed research avenues11. The method 
outlined by Cromwell et al. was selected and applied to 
identify a set of themes to be evaluated, with each theme 
including specific criteria. In brief, M.B., M.M.K. and 
S.L.D. reviewed the most common domains and cri-
teria and clarified their definition from the literature, 
which was used to ascertain a shared understanding 
for the application process. The initial criteria list was 
further refined as suggested by Marsh et al.14, whereby 
considerations were given to the pro perties of: com-
pleteness — criteria should capture all factors relevant 
to the decision; non-redundancy — criteria should be 
removed if they are unnecessary or judged to be unim-
portant; non-overlap — criteria should be defined to 
avoid double counting; and preference independence 
— how much one cares about the performance on a 
criterion should not depend on the performance of 
other criteria. Based on the logic derived from available 
research best practice, the list of prioritization criteria 
was finalized with the LAC via teleconference, ahead of 
the face-to-face workshop (Table 1).
Face-to-face workshop
The workshop began with four rounds of group dialogue 
that helped to define the context of this landscape analy-
sis initiative and encouraged the participants to consider 
Movember’s perspective as a research funder to maximize 
outcomes and patient benefit from its prostate cancer 
biomedical research investments. The considerations for 
Movember were: what would success look like in 5 years’ 
time? What are the existing barriers in the research field? 
What would be the optimal investment strategy? And 
how could Movember collaborate with other funders to 
exert a collective impact on the field? (box 2).
LAC members then independently evaluated all 
research needs against the five agreed prioritization cri-
teria to determine their importance, marking each with a 
“yes” (important), “no” (not important) or “not qualified 
to answer”11. In a facilitated group dialogue, any research 
need that had a low level of agreement was re-evaluated 
and the rationale that supported and/or opposed each 
criterion was discussed. A second round of scoring was 
then conducted and a new count was carried forwards 
for final consideration. Thus, each research need received 
a prioritization score between 0 and 5, in which a score 
of 1 was allocated to each “yes” and a 0 score allocated 
for each “no” or “not qualified to answer” (Table 2; fig. 1).
Analysis and discussion
The stakeholder interview rankings were plotted against 
the prioritization scores to identify the most important 
research needs (fig. 2). From this analysis, 17 research 
needs were identified by the LAC. The highest scor-
ing research needs were in the treatment optimization, 
screening and early diagnosis, localized disease and 
oligometastatic disease fields (each of these needs were 
mentioned at least four times during stakeholder inter-
views and received a prioritization score of 4 or 5 by the 
LAC). These fields are predominantly (but not solely) 
applicable to the early stages of prostate cancer, which 
affects the most men and their families.
Of the identified research needs, the maximum pri-
oritization score of 5 was received by research needs 
number 1: establish more sensitive and specific tests 
to improve disease screening and diagnosis; number 2: 
develop indicators to better stratify low-risk prostate 
cancer in determining which men should go on active 
surveillance (AS), and number 15: integrate companion 
diagnostics into randomized clinical trials to enable 
prediction of treatment response. These highest prior-
ity research needs are discussed in detail to highlight the 
Box 1 | list of stakeholders involved in the landscape analysis
Interview stakeholders 
•	Men with prostate cancer (9 men)
•	Health economists (3 individuals)
•	epidemiologists (3 individuals)
•	urologists (8 individuals)
•	Medical oncologists (6 individuals)
•	radiation oncologists (3 individuals)
•	Pathologists (2 individuals)
•	Foundation or health organization representatives (7 individuals)
•	research academics (9 individuals)
•	industry representatives (3 individuals)
landscape Analysis Committee members
•	Peter L. Choyke (usa), Chief, Molecular imaging Program, Center for Cancer 
research, National Cancer institute, National institutes of Health
•	suneil Jain (uK), Clinical reader and Honorary Consultant in Clinical Oncology, 
Patrick G Johnston Centre for Cancer research, Queen’s university Belfast
•	Guido w. Jenster (Netherlands), Professor, experimental urological Oncology; 
Director, experimental urology Laboratory, erasmus MC
•	Bertrand tombal (Belgium), Chairman and Professor, Division of urology, université 
Catholique de Louvain, Cliniques universitaires saint-Luc in Brussels; President, 
european Organization for research and treatment of Cancer
•	Beatrice s. Knudsen (usa), Professor, Pathology, university of utah; Medical Director 
of Digital and Computational Pathology, aruP national reference laboratory
•	Charles J. ryan (usa), Professor, Medicine, Division of Hematology, Oncology and 
transplantation, university of Minnesota
•	Jeremy L. Millar (australia), Director, radiation Oncology alfred Health; Professor, 
Central Clinical school, Monash university; Clinical Lead, Prostate Cancer Outcomes 
registry, Monash university; Deputy Chair, Cancer Council australia; Director, 
Cancer Council australia
•	tony Crispino (usa), Prostate Cancer survivor; President — us tOO Prostate Cancer 
support and education Las vegas Chapter; swOG Cancer research Network Patient 
advocate
•	Nicole Mittmann (Canada), Chief scientist and vice-President of evidence standard, 
Canadian agency for Drugs and technologies in Health and Department of 
Pharmacology and toxicology, university of toronto
Names listed in the acknowledgements section.
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identified gaps and outline potential opportunities for 
future collective effort.
Research need number 14 (further progress precision 
medicine) was mentioned considerably more often than 
others during the stakeholder interviews (32 mentions) 
and certainly reflects the current view of the research 
community, with approximately 500 review articles on 
“prostate cancer precision medicine” published between 
2017 and 2019. However, whilst the notion of offering a 
man with prostate cancer the most effective medicine at 
the optimal time based on his individual genomic profile 
is highly desirable, precision medicine only received an 
overall prioritization score of three as a research need, 
as the LAC did not feel it could be strongly supported by 
the current state of knowledge (research prioritization 
criteria: implementable) nor would it particularly help 
to address the research prioritization criteria around 
health inequities. This thinking continues to be relevant, 
as despite progress in the field of precision medicine 
in prostate cancer (such as the FDA approval of PARP 
inhibitors for men with germline or somatic homologous 
recombination repair (HRR) gene mutations15,16), consid-
erable effort is still needed for precision oncology to be 
broadly applicable to men around the world and for val-
idated biomarkers to be capable of realizing a truly per-
sonalized treatment approach17. It should be noted that, 
although the concept of ‘health inequities’ was an agreed 
prioritization criterion and was a component of the 
LAC prioritization discussions at the face-to-face work-
shop, it was not a component of the stakeholder inter-
views per  se. During the workshop, research need 
number 14, was deemed incredibly important, but was 
considered to have a low capacity to address health ineq-
uities on a global scale, particularly owing to the high 
pricing of precision tests and biomarkers and accom-
panying novel therapies in the USA. Without sufficient 
nationwide health insurance in the USA, precision 
medicine elements such as biomarkers, novel imaging 
agents and some novel therapies were thought to be very 
often unaffordable for many patients. Patient access to 
and reimbursement of new oncology therapies is var-
ied in Organisation for Economic Co-operation and 
Development countries and can take many years after 
first marketing approval is granted, typically in the USA18.
Opportunities to prevent disease progression to 
life-threatening advanced disease exist during the transi-
tional state between localized disease and oligometastatic 
disease. Research need number 10 (to more accurately 
define oligometastatic prostate cancer and determine 
the best treatment strategy) was highly prioritized by the 
LAC (fig. 2) and is a very active research topic with 
numerous important clinical trials being conducted 
in this area (such as SWOG S1802 (ref.19), ORIOLE20, 
STOMP21, RAVENS22, STORM23, FORCE24). It is hoped 
that these trials will lead to enhanced detection of disease 
recurrence, as well as improved use of biological and/or 
imaging biomarkers, enabling the delivery of potentially 
curative treatments, which will reduce the number of 
men progressing to more advanced and lethal disease.
Perspectives of men with prostate cancer
Interviews revealed that living with prostate cancer 
can considerably affect a man’s physical and mental 
well-being. In general, men were satisfied with the qual-
ity of the health-care services they received. Connecting 
with other men with prostate cancer was generally 
thought to be highly valuable by the men who were 
interviewed; however, the selected interviewees’ views 
might not be reflective of all men with prostate cancer. 
Feedback from interviewees suggested that the provi-
sion of quality health information to support improved 
informed decision-making was crucial for men to feel 
an increased sense of ownership of their own health. 
Additionally, Movember was thought to be best placed 
to further support this provision by raising awareness of 
prostate cancer and ensuring that high-quality informa-
tion is available for the general public. Men highlighted 
that there were elements of confusion during particular 
stages of disease management. Specifically, they men-
tioned the need to improve clarity of population screen-
ing guidelines, the need for improved diagnostic tools 
to distinguish aggressive and indolent prostate cancer, 
the need to standardize treatment approaches, and nec-
essary improvements in the broader implementation of 
treatment guidelines within their own countries. One 
man also suggested that clinical trials in prostate can-
cer could be conducted more efficiently by improving 
clinical trial networks. Other suggestions to improve 
research included exploring the repurposing of existing 
drugs and research that will minimize the long-term use 
of androgen deprivation therapy (ADT) and its associ-
ated adverse effects. Men also suggested that measures 
to reduce racial, socioeconomic and regional dispari-
ties should be embedded into the delivery of research 
Box 2 | Interview questions and lAC workshop discussion topics
Interview questions for men with prostate cancer
invite men to share their experience with prostate cancer, including diagnosis, 
treatment and support received in both clinical and survivorship care, awareness of 
clinical trials available and most significant challenges and/or barriers. ask each man  
a series of standardized questions:
1. what are the gaps or roadblocks that prevent advances in the prostate cancer space 
and what do men think could be done to address the gaps?
2. what aspects of biomedical prostate cancer research should Movember invest in 
that would have helped their experience with prostate cancer?
3. what would success look like in 5 years’ time?
Thought leader interview questions
1. where is the field of prostate cancer research and health care likely to be over the 
next 3–5 years?
2. where is the existing momentum?
3. what are the research gaps that need addressing to move the field forwards?
4. where should Movember invest over the next 3–5 years to have the greatest 
impact?
5. where can Movember best coordinate a collective impact-style approach to 
consolidate the field and maximize patient outcomes?
6. in what areas are other funders investing in the space?
7. what are current barriers in conducting clinical trials in prostate cancer?
Movember considerations and discussion at workshop
1. what would success look like in 5 years’ time?
2. what are the existing barriers in the research field?
3. what would be the optimal investment strategy?
4. How could Movember collaborate with other funders to exert a collective impact in 
the field?
LaC, Landscape analysis Committee.
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and health care. Lastly, it was suggested that Movember 
should continue to engage with other funders, govern-
ments and industry to promote synergies, maximize 
research impact and avoid duplication of effort.
Consensus on identified research needs
The culmination of the landscape analysis was consen-
sus on 17 research needs in the field of prostate cancer 
research. The LAC scored each research need against 
the five prioritization criteria (fig. 2), which have been 
reviewed in detail by Movember. Future investments by 
Movember into new prostate cancer biomedical research 
initiatives that address these different research needs will 
be made in the context of existing programmatic invest-
ments, as well as ongoing and planned programmatic 
investments by other global funding bodies, with the 
aim of reducing duplication of effort and maximizing 
patient outcomes. The 17 research needs are described 
and categorized based on their relevant stage of disease.
Screening and early diagnosis
Early identification of cancer typically enables improved 
implementation of treatment options, resulting in 
improved clinical outcomes, including increased overall 
survival. However, without a reliable, minimally inva-
sive test for risk assessment and diagnosis of clinically 
Table 2 | research needs by disease stages
Disease stage research need 
number




Screening and early 
diagnosis 1





Develop indicators to better stratify low-risk prostate cancer in 
determining which men should go on active surveillance
18 5
3








Improve current standard-of-care treatment (radiotherapy and 
surgery) to maximize patient mental and physical well-being
NA 3
6





Determine the most effective way of treating biochemical 




Improve the use of androgen deprivation therapy to minimize 
adverse effects of treatment
4 3
9





More accurately define oligometastatic prostate cancer and 




Determine the optimal treatment sequence for men with 














Further progress precision medicine such as use of biomarkers 
that can enable personalized treatment decision
32 3
15
Integrate companion diagnostics (for example, liquid and/or 
tissue biopsy and imaging modalities) into randomized clinical 
trials to predict treatment response
5 5
16
Demonstrate clinical utility of validated liquid biopsies NA 4
17
Replace tissue biopsies with non-invasive biomarkers (such as 
liquid biopsy or imaging modalities)
NA 3
Research needs in a solid circle are insights from the stakeholder interviews that were prioritized for workshop discussion (those mentioned by four or more 
interviewees); research needs in an open circle are the LAC's recommendation for discussion. LAC, Landscape Analysis Committee; mCRPC, metastatic 
castration-resistant prostate cancer; NA, not available.
www.nature.com/nrurol
C o n S e n S u S  S tat e m e n t
significant prostate cancer, population-based screening 
will likely subject too many men to unnecessary treat-
ment and avoidable adverse effects, with the risk of 
aggressive disease still being overlooked. Thus, the need 
to establish more sensitive and specific tests to improve 
disease screening and diagnosis (research need 1; LAC 
score 5) was highly prioritized by the LAC. Inclusion of 
diagnostic parameters in prostate cancer risk calcula-
tors, improved use of novel imaging to improve biopsy 
accuracy, examination of germline mutations to identify 
high-risk subpopulations, or adoption of a suite of molec-
ular urine and blood biomarkers are all opportunities 
that should be explored.
Active surveillance
Safely delaying or avoiding unnecessary treatment for 
a select population of men with low-risk (and poten-
tially intermediate-risk) prostate cancer through AS is 
widely accepted as a suitable management approach. 
However, uncertainty still remains regarding which 
patients should be enrolled to AS protocols, the opti-
mal follow-up schedule for patients based on individual 
risk, the best strategies to mitigate anxiety and reduce 
the number of men switching to active treatment if they 
are not progressing, as well as the economic cost bene-
fits and value. In order to improve management of men 
with clinically insignificant disease on AS, it was deemed 
critical to develop indicators to better stratify low-risk 
prostate cancer and help determine which men should 
go on AS (research need 2; LAC score 5), standardize AS 
guidelines to aid decision-making (research need 3; LAC 
score 4) and educate men about the benefits of AS and 
ways of reducing anxiety (research need 4; LAC score 4).
Localized disease
Men diagnosed with high-risk prostate cancer are gener-
ally offered surgery and/or radiotherapy with a curative 
intent in the Organisation for Economic Co-operation 
and Development countries25. However, the survival 
benefits from these primary treatments are also asso-
ciated with significant adverse side effects, including 
urinary, sexual and bowel dysfunction25. Improving 
current standard-of-care treatment to maximize men’s 
mental and physical well-being (research need 5; LAC 
score 3) was identified as an unmet research need to help 
mitigate the substantial patient burden of these common 
adverse outcomes. During the interview process, some 
stakeholders suggested that determining the interplay 
between genetic and lifestyle factors in driving disease 
progression (research need 6; LAC score 1) should be a 
key research focus, but this was not ranked a high priority 
by the LAC.
Locally advanced disease
Approximately 20–40% of men who undergo either sur-
gery or radiation therapy progress to a state of biochem-
ical recurrence, as signified by a rise in their serum PSA 
level26,27. Advancement in novel imaging technologies, 
including multiparametric MRI (mpMRI) and novel 
PET tracers have revolutionized the diagnosis of bio-
chemical recurrence28,29. Lesions located in the prostate 
bed or nodal, bony or visceral sites can now potentially 
be detected in men using novel imaging long before 
their PSA level reaches the threshold of 0.2 ng/ml (ref.30). 
However, the ability to detect disease recurrence much 
earlier using imaging now means that conventional 
treatments that would have previously been prescribed 
without this additional information, might no longer 
be adequate or optimally timed. Thus, the LAC agreed 
that it is important for the field to use these new tools to 
determine the most effective way of treating biochemi-
cal recurrence in order to improve survival and enhance 
QOL (research need 7; LAC score 3) but also to improve 
the use of ADT to minimize treatment-related adverse 
effects (research need 8; LAC score 3). The LAC also 
felt that in the locally advanced setting, there was an 
opportunity to perform genomic profiling earlier in the 
therapeutic pathway in order to optimize treatment and 
identify likely responders to therapy (research need 9; 
LAC score 3).
Oligometastatic disease
Advances in novel imaging techniques have also enabled 
accelerated research progress and knowledge in the field 
of oligometastatic prostate cancer. Consensus on defin-
ing the oligometastatic disease state and the opportunity 
it presents to potentially ‘cure’ the disease remain con-
tentious within the research and clinical community31. 
Aggressive metastasis-targeted approaches are being 
extensively investigated to understand their efficacy to 
ablate detected lesions and reduce the spread of further 
metastases32,33. Some experts believe that oligometa-
static disease is simply an indicator that the disease has 
progressed to be systemic and is no longer amenable 
to metastasis-targeted therapy31. Targeted, high-dose 






























































Fig. 2 | Summary of prioritized research needs from the landscape analysis. Each 
research need, ordered according to its relevant disease stage, was plotted by the 
number of times it was mentioned in the thought leader and patient interviews (x axis) 
against the prioritization score it was given by the Landscape Analysis Committee (LAC;  
y axis). Research needs in a solid circle are insights from the stakeholder interviews that 
were prioritized for workshop discussion (those mentioned by four or more interviewees); 
research needs in an open circle are the LAC’s recommendation for discussion.
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emerging to be a safe and effective option in delaying 
systemic ADT with or without chemotherapy34. Further 
large-scale studies that validate the findings from early 
stereotactic ablative radiotherapy trials and enable a 
more accurate definition of oligometastatic prostate can-
cer and determine the best treatment strategy (research 
need 10; LAC score 4) was very highly prioritized by 
the LAC.
Advanced disease
Men with advanced prostate cancer face a poor prog-
nosis and increased risk of treatment-incurred adverse 
effects. Targeting the androgen receptor (AR) signalling 
pathway remains the most universally effective means of 
achieving disease control. Results from large phase III tri-
als have demonstrated that men with hormone-sensitive 
prostate cancer treated with novel AR-targeted ther-
apies and ADT35–37 do better than men treated with 
ADT alone, which has now become standard of care. 
However, only a limited number of treatments are avail-
able once men progress on ADT and, depending on 
which therapy has been used in the hormone-sensitive 
stage, available treatment choices for men with meta-
static castration-resistant prostate cancer (mCRPC) 
can still be limited38,39. Studies are already underway to 
address this critical challenge, including a crossover trial 
that has provided essential evidence that the sequence of 
abiraterone (plus prednisone) before enzalutamide was 
associated with longer time to second PSA progression 
than the reverse sequence40. Comprehensive studies will 
be required in order to determine the optimal treatment 
sequence for men with advanced disease that will lead 
to the best outcomes for a man’s specific tumour type 
(research need 11; LAC score 3). Clinical quality regis-
tries, such as the Movember-funded IRONMAN study, 
will also help to address this question and ultimately 
lead to better outcomes for men with advanced prostate 
cancer41.
A variety of novel approaches continue to be explored 
in the advanced disease setting. In addition to promising 
outcomes with PARP inhibitors42,43 and PSMA-targeted 
theranostics44, the potential of immunotherapy as a 
treatment option for men with mCRPC (research need 
12; LAC score 1) is of particular interest, despite dis-
couraging initial trial results in prostate cancer com-
pared with the effects in other tumour types. Efficacy 
and safety of various immunotherapies, including vac-
cines, immune checkpoint inhibitors, virus-mediated 
immune modulation and adaptive T cell therapy, are 
being investigated as monotherapies or combination 
therapies. As of April 2020, a search for “prostate can-
cer metastatic” AND “immunotherapy” revealed 34 
active clinical trials on clinicaltrials.gov (including tri-
als that are ‘recruiting’, ‘not yet recruiting’ and ‘active 
not recruiting’). Although these trials are still years 
away from revealing any meaningful clinical outcomes, 
substantial progress can be expected in this field over 
the next decade to unravel ways of priming the tumour 
immune response for effective immunotherapies45. The 
LAC felt that the development of such agents should be 
the realm of industry rather than funding bodies such 
as Movember.
Disease biology and treatment optimization
Considerable improvement in prostate cancer treat-
ment and management has been made over the past 
decade following discoveries in biomedical and clinical 
research. These discoveries have been realized through 
continuous investigation of key aspects of the underly-
ing biology of the disease. As health care enters the era 
of precision medicine, an improved understanding of 
the biology of disease progression will be important for 
optimizing treatment decisions (research need 13; LAC 
score 3). Owing to the critical role of biomarkers in ena-
bling precision medicine, their development and clinical 
utility constituted a strong theme running through this 
landscape analysis. Thus, the need to further progress 
precision medicine, such as the use of biomarkers that 
can enable personalized treatment decisions (research 
need 14; LAC score 3), was identified as a key area of 
research warranting further investigation and fund-
ing, during stakeholder interviews and by the LAC. 
Furthermore, integration of companion diagnostics 
(for example, liquid and/or tissue biopsies and imaging 
modalities) into randomized clinical trials to predict 
treatment response (research need 15; LAC score 5) 
scored the maximum prioritization score by the LAC. 
Although a large number of liquid biopsies have been 
developed (or are currently in development) to better 
inform patients and clinicians about a tumour’s clinical 
significance and current state of progression, few have 
effectively entered the mainstream health-care system to 
a point where they are being routinely used to optimize 
treatment decisions as a universal standard of care46. 
A critical next step is, therefore, to demonstrate the 
utility of these validated liquid biopsies (research need 
16; LAC score 4) if they are to have a real effect on the 
health outcomes of all men, irrespective of their region 
or socioeconomic status. One specific area that the LAC 
felt had considerable potential for a positive effect was 
to replace tissue biopsies with non-invasive biomarkers, 
such as liquid biopsy or imaging modalities (research 
need 17; LAC score 3), but, as outlined above, this 
endeavour is not without significant challenges.
Highest priority research needs
Maximum prioritization (a score of 5) was given to 
three research needs by the LAC. The highest priority 
research needs are research need number 1: establish-
ing more sensitive and specific tests to improve low-risk 
disease screening and diagnosis; research need number 
2: developing indicators to better stratify low-risk pros-
tate cancer in determining which men should go on AS; 
and research need number 15: integration of companion 
diagnostics in randomized clinical trials to enable pre-
diction of treatment response. These research needs have 
been considered in a contemporary context.
Research need number 1
Establishing more sensitive and specific tests to improve 
low-risk disease screening and diagnosis. PSA screen-
ing is a highly controversial topic in urology; screening 
guidelines are often not population-based and vary 
in their recommendations in different jurisdictions47. 
Virtual consensus is exhibited across all clinical screening 
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guidelines that PSA testing should not occur without 
shared decision-making between the clinician and 
patient48. The goal of prostate cancer screening is to iden-
tify those men with clinically significant localized disease 
who can be successfully treated, thereby preventing the 
morbidity and mortality associated with advanced or 
metastatic cancer. Identifying those men with low-risk, 
localized disease who can be managed appropriately 
using AS in order to avoid treatment-associated adverse 
effects is another key objective. Currently, 20–50% of 
men diagnosed with prostate cancer as a result of screen-
ing are likely to be overtreated49. These statistics high-
light the importance of shared decision-making between 
men and their primary health-care professional, in which 
each individual man is independently assessed for his 
need to have PSA testing and the timing thereof, taking 
into account those men at an increased risk of develop-
ing prostate cancer owing to their family history and/or 
ethnicity (for example, men of Afro-Caribbean descent 
are at an increased risk of developing prostate cancer)50.
Growing evidence suggests that improved risk strat-
ification using biomarker models can improve prostate 
cancer diagnosis. Numerous FDA-approved blood-based, 
urine-based and exosome-based diagnostic biomarkers 
(for example, Prostate Health Index51 and PCA352) or 
CLIA-certified (such as 4 K score53, SelectMDX54 and 
ExoDx55) have demonstrated superiority to PSA testing in 
reducing the harms of prostate cancer testing. However, 
the population-wide adoption of these tests has faced a 
variety of challenges, including a need for extensive vali-
dation and cross-validation, different biomarker utilities 
in multiple clinical contexts and therapies, access and 
affordability issues, and a lack of head-to-head biomarker 
comparisons in prospective trials56.
Novel biomarkers with fewer false-positives and more 
sensitive detection of high-grade cancers than PSA are 
currently being tested in prospective, population-based 
trials. The STHLM3 study demonstrated a 32% reduc-
tion in the number of biopsies in 59,000 Scandinavian 
men who were tested with a panel of blood-based bio-
markers compared with PSA testing alone, without loss 
in detection sensitivity57. Furthermore, in a meta-analysis 
comprising 46 clinical trials and 12,295 subjects evalu-
ating urine PCA3 mRNA levels, the marker was found 
to have good diagnostic performance (0.73 sensitivity, 
0.65 specificity, 0.75 area under curve) in diagnosing 
prostate cancer58. The Prostate Health Index test is effec-
tive in cancer risk stratification in European and Asian 
men and different reference ranges have been developed 
for the different ethnic groups59. Presently, widespread 
clinical adoption and cost effectiveness in multiple juris-
dictions are yet to be realized for these tests and future 
stud ies are, therefore, essential to ascertain whether these 
tests are clinically applicable across diverse populations 
and health-care systems.
Developments in imaging technology are demonstrat-
ing considerable improvements in the diagnosis, grading 
and monitoring of prostate cancer. High-quality evidence 
has shown that MRI can reduce the number of men who 
require a prostate biopsy and also reduce the diagnosis of 
clinically insignificant cancers that are unlikely to cause 
harm. A Cochrane systematic review and meta-analysis 
found that MRI with or without MRI-targeted biopsy 
compared with systematic transrectal ultrasonography- 
guided biopsy could increase true positive detection by 
14% and decrease false-negative detection by 25% in 
men suspected of having pro state cancer60. In support 
of the use of imaging, the Prostate Imaging Reporting 
and Data System (PI-RADS) Steering Committee out-
lined how the MRI pathway should be incorporated 
into routine clinical practice, recommending that 
high-quality PI-RADS-compliant mpMRI should be 
performed before biopsy in most men suspected of 
having clinically important disease, who are likely to be 
offered active treatment61. mpMRI can provide multi-
ple benefits over invasive transrectal ultrasound-guided 
biopsy, such as better distinguishing between clinically 
significant and insignificant tumours, a reduction in the 
number of biopsies performed and associated complica-
tions, improved biopsy accuracy, as well as potential cost 
savings62,63. mpMRI has been found to be both clinically 
effective and cost effective by the UK National Institute 
for Health and Care Excellence64. In the UK, 72% of 
men with suspected prostate cancer are currently being 
offered the scan before a biopsy65. Issues with interpreta-
tion and image quality, such as MRI-reading experience 
and lack of universally accepted technical quality criteria 
for prostate MRI are current barriers that still need to be 
addressed61,66. Future studies to understand the clinical 
effect that the implementation of MRI into routine work-
flows will have on the long-term health outcomes of men 
suspected of having prostate cancer are crucial.
The development, use and integration of imag-
ing modalities with blood-based, tissue-based and 
urine-based biomarkers will also enable potential 
improvements in the identification and subsequent 
treatment of clinically significant lesions, as well as the 
detection and management of low-risk disease. The 
UK-based ReIMAGINE consortium67, which is aimed at 
integrating data from MRI and molecular biomarkers to 
further improve risk stratification and to reduce the over-
all costs of prostate cancer care, is currently investigating 
this possibility.
Establishing and adopting tests with improved sen-
sitivity and specificity for prostate cancer screening and 
diagnosis might prove to be complex, but considerable 
benefit could be gained for men with prostate cancer and 
the wider health-care system, and this need should be a 
key area of future research focus.
Research need number 2
Develop indicators to better stratify low-risk prostate 
cancer in determining which men should go on active 
surveillance. The concept of AS was first introduced in 
the early 2000s and has since become widely accepted 
as the standard of care for the management of men diag-
nosed with low-risk, localized prostate cancer68. In addi-
tion, it is postulated that AS might be a better option than 
aggressive clinical treatment for a subset of men with 
favourable, intermediate-risk disease, as it avoids the risk 
of detrimental urinary, bowel and sexual adverse effects 
of active therapies and consequently improves QOL64. 
Although several trials have been conducted in men with 
intermediate disease, further research incorporating 
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the inclusion of advanced imaging modalities and bio-
markers, which are increasingly being used to diagnose 
prostate cancer, are necessary to refine the criteria and 
better understand which men at intermediate risk should 
receive AS69–71.
Currently, men on AS are typically monitored 
using longitudinal evaluation of their serum PSA lev-
els, imaging and tissue biopsies to ensure appropriate 
risk-classification (and re-classification) and, when 
necessary, selection for intervention if the disease has 
progressed72. However, a lack of consensus that defines 
this risk classification has led to substantial variation in 
AS protocols between and even within countries73–75. 
This variation is attributed to differences in risk strat-
ification and inclusion criteria for AS, which are pri-
marily based on a range of clinical assessments, which 
include Gleason grade pathology, imaging (mpMRI), 
and genomic assessments of tissue, blood and/or 
urine76. However, given that tissue biopsies commonly 
under-represent disease severity77,78, improvements 
in the accuracy of risk stratification and patient selec-
tion for AS are crucial. Molecular-based assays, such as 
Decipher, Oncotype, Prolaris and ProMark, are included 
in National Comprehensive Cancer Network guidelines 
and can be considered for men with low-risk (Gleason 
grade 3 + 3), or low-volume intermediate disease 
(Gleason grade 3 + 4) to improve risk stratification79 but 
have not yet been widely adopted. This lack of adoption 
is due to controversy regarding how to integrate data 
from these novel diagnostic tests into clinical practice 
and decision-making, as they were not originally devel-
oped for AS populations and might not be optimized 
for this setting. The use of mpMRI has become central 
in the management of prostate cancer and is included in 
many AS protocols to improve risk stratification and 
patient selection80,81. Studies have demonstrated that 
mpMRI-targeted biopsies are more accurate at detecting 
clinically significant disease with greater efficiency than 
biopsies alone and that detection of a lesion with mpMRI 
increases the likelihood of detecting high-risk disease 
at subsequent biopsy82–84. As such, mpMRI is used in 
several AS protocols to guide clinical decision-making. 
Selecting patients on AS using mpMRI remains a chal-
lenge with various screening measures and risk strati-
fication methods currently in use, each with their own 
inclusion criteria and definitions of disease progression. 
Further studies on the optimization of mpMRI in the 
management and selection of men on AS are necessary.
In an effort to reduce the variation between AS pro-
tocols, a collective of prostate cancer-related European 
medical associations representing urology, nuclear med-
icine, radiotherapy, oncology and geriatric oncology 
formed a Prostate Cancer Guideline Panel and initiated 
a protocol-driven, three-phase study, in which consen-
sus was achieved on 93 of 129 statements85. Consensus 
statements were formulated covering criteria as broad 
as patient selection, inclusion and exclusion criteria 
(including patient and disease characteristics, imaging 
and type of biopsy), the nature and timing of investiga-
tions and assessments during the period of monitoring 
and follow-up assessment (including PSA measure-
ments, clinical examination, repeat imaging and repeat 
biopsies), criteria and thresholds for reclassification and 
change in management, and type of outcome measures 
to be prioritized85. Until higher levels of evidence emerge 
through prospective comparative studies, the findings 
from the Prostate Cancer Guideline Panel will be useful 
to inform routine clinical practice.
Despite AS being a viable option to safely reduce the 
overtreatment of low-risk disease, the continuous mon-
itoring of men has been described as a considerable 
burden for many patients with repeat biopsy adherence 
decreasing over time, independent of biopsy frequency86. 
This observation highlights a fundamental need to 
develop more accurate, non-invasive and personalized 
approaches that are tailored to individual men on AS. 
Risk calculators, such as the Canary Prostate Active 
Surveillance Study risk calculation87, the Johns Hopkins 
model88 and the PRIAS model89 have been developed in 
an effort to address this need. These AS risk calculators 
can selectively predict men at risk of progression and 
balance reclassification detection with the number of 
surveillance biopsies by incorporating the serial meas-
urement of the monitoring tools into the prediction 
model (for example, patient age, prostate volume, PSA, 
time since diagnosis, number of previous biopsies and 
all previous biopsy results)90–94.
Improvements in survivorship support, including 
a more dynamic and personalized approach to moni-
toring, could reduce cancer-related anxiety, which has 
been identified as a key factor in the discontinuation 
of AS86. The collection of patient-reported outcome 
measures from men with prostate cancer through local 
and global clinical registries will also be an important 
source of real-world evidence to improve the quality of 
care and optimal management of men undergoing AS. 
When large datasets are analysed and the knowledge dis-
seminated accordingly, these patient-reported outcome 
measures will help to identify important considerations 
such as cancer-related anxiety that need to be addressed 
to ultimately improve QOL and clinical practice. It is 
anticipated that these registries will highlight potential 
areas of patient need where relevant strategies can be 
implemented to improve the care of patients.
The Movember-funded Global Action Plan 3 on 
AS (GAP3) was initiated to support ongoing research 
in this dynamic area. The retrospective data from over 
20,000 men on AS have been included in the study to 
date, becoming one of the largest pooled prostate can-
cer AS cohorts in the world95. The GAP3 dataset has 
been used to report findings on protocol adherence 
for low-risk disease96, reasons for discontinuation of 
AS97, biopsy grading consistency98 and validation of AS 
reclassification calculators99.
Research need number 15
Integration of companion diagnostics in randomized 
clinical trials to enable prediction of treatment response. 
Novel therapeutic options for advanced prostate can-
cer have dramatically increased during the past decade. 
Men with mCRPC have improved overall survival when 
treated with therapies that target the AR100,101. Emerging 
prostate cancer therapies such as immune checkpoint 
inhibitors and PARP inhibitors, which were recently 
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approved by the FDA, also elicit clinical responses, but in 
smaller subsets of men with mCRPC than AR-targeting 
therapies102,103. These new agents for advanced prostate 
cancer could deliver other benefits to men (includ-
ing response prediction, decreased adverse effects and 
decreased financial toxicity) if predictive biomarkers 
were used to guide therapy decisions. Men with advanced 
disease have increased volumes of material originating 
from their tumour in their circulation (such as circulat-
ing tumour cells (CTCs) and circulating tumour DNA 
(ctDNA))104, allowing blood-based biomarker assays to 
be developed. These liquid biopsies, including AR-V7 
CTC test (Epic Sciences), CellSearch (Veridex) and Adna 
test (Qiagen) provide advantages over tissue biopsy as 
they are less invasive and can be routinely collected, 
enabling the real-time evaluation of tumour burden and 
genomic status105. This evaluation in real time is particu-
larly relevant as, inevitably, tumours develop treatment 
resistance over time. Real-time monitoring enables 
identification of the development of tumour resistance, 
meaning that more informed second-line and third-line 
treatment decisions can be made.
An example of a predictive biomarker with demon-
strated clinical utility is the commercially available 
AR-V7 test, which predicts the likelihood that a man with 
mCRPC will not benefit from the AR-targeted therapies 
enzalutamide and abiraterone, based on the expression 
level of the AR splice variant 7 mRNA in CTCs106. This 
test is being used by physicians in clinical practice and can 
be reimbursed through Medicare in the USA. The AR-V7 
test has yet to receive FDA approval owing to a lack of 
consensus on the interpretation of the test and prospective 
evidence of overall survival107. AR-targeted therapies are 
now increasingly used in earlier stages of disease, includ-
ing FDA approval for metastatic castration-sensitive and 
non-metastatic castration-resistant disease. To ensure 
that therapies remain effective, identifying and monitor-
ing resistance with validated predictive biomarkers and 
incorporating these as companion diagnostics into pro-
spective clinical trials to improve prediction of treatment 
response will be crucial.
The declining cost of sequencing technologies 
means that an unprecedented opportunity exists for 
personalized genomic profiling and tumour monitor-
ing. Concordance between AR mutations in ctDNA and 
matched patient tissue biopsies is high, supporting the 
development of DNA biomarkers to guide the manage-
ment of patients with mCRPC based on ctDNA alone108. 
A particular area of promise is the serial monitoring of 
AR alterations and AR mutation status that could ena-
ble the detection of treatment resistance before clini-
cal progression109. Evaluation of ctDNA could help to 
define the role of homologous DDR mutations, which 
affect ~20% of patients with mCRPC and could be tar-
geted using PARP inhibitors110. Germline mutations are 
readily detectable in leukocytes, but somatic mutations 
(reversion mutations and homozygous deletions) can be 
detected in ctDNA, enabling their clinical relevance to 
be delineated and the development of treatment resist-
ance to be identified111. Hypermutations and microsatel-
lite instability can also be detected in ctDNA and could 
be useful for predicting response to immune checkpoint 
inhibitor therapies; they are, therefore, promising 
biomarkers worthy of further exploration112.
Biomarker analysis is increasingly being imple-
mented in the protocols of investigator-led trials (includ-
ing STAMPEDE113, ProBIO114 and PC-BETS115) in order 
to improve treatment selection and monitor resistance. 
As liquid biopsy development continues, opportuni-
ties will become available to maximize multimodal 
approaches such as genetic sequencing and proteomic 
characterization of CTCs and exosomes, in order to 
increase the understanding of real-time tumour status116. 
CTC characterization and sequencing will be validated 
using ctDNA assessments in a longitudinal manner 
to improve understanding of tumour heterogeneity, 
enabling the optimal treatment of advanced prostate 
cancer. Enhanced collaboration between researchers, 
pharmaceutical companies, diagnostics companies, 
not-for-profit foundations and regulators, as well as 
increased patient engagement, will be essential for 
realizing these opportunities for the benefit of patients.
Limitations
A number of limitations and caveats should be considered 
when interpreting this landscape analysis. First, the scope 
of this analysis was restricted to biomedical and clinical 
research areas and excluded survivorship research or clini-
cal quality initiatives such as patient registries. Second, the 
prostate cancer treatment landscape is changing rapidly 
and the field has seen practice change in the past 3 years 
since the landscape analysis took place. Consequently, 
some research needs identified at the time of the analysis 
might not adequately reflect the current field. However, 
this report is current at the time of publication. Third, 
the identified research needs are probably most relevant 
in well-resourced health-care settings, where high-quality 
routine clinical care is standard, but could be less appli-
cable to developing countries, as the landscape analysis 
was primarily designed to improve understanding of the 
research gaps and opportunities so that Movember can 
implement programmes in countries in which it currently 
fundraises and operates (which will hopefully also have a 
future positive impact on a global scale). Fourth, this land-
scape analysis was conducted by Movember as an organi-
zation that operates internationally; thus, country-specific 
nuances might not have been taken into consideration. 
Finally, some degree of overlap between certain closely 
linked research needs is inevitable. For example, a need 
for more accurate diagnostic tests might also have impli-
cations for research needs related to precision medicine, 
disease diagnosis and disease recurrence.
Future directions
The LAC recommended that Movember focus its future 
prostate cancer biomedical research investments on 
research areas that lead to the early identification and 
optimal clinical management of men diagnosed with 
prostate cancer. This recommendation was proposed to 
the Movember GSC in February 2018.
The GSC agreed with the LAC’s recommendation 
and also felt that there was a need for Movember to con-
tinue to invest in translational research that will lead to 
an improved understanding of the biology of the disease 
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and new or improved targets for CRPC, in order to ena-
ble optimal treatment of men who progress to advanced 
disease.
Moving towards its 2030 goal, Movember has com-
bined the LAC’s and the GSC’s recommendations to 
establish two strategic priorities for future biomedical 
research investment. New investments will be made 
in highly translational research programmes that will 
lead to the earlier identification and optimal treatment 
of men with clinically significant disease in order to 
reduce the number of men progressing to advanced dis-
ease (strategic priority 1), as well as programmes with 
a focus on new or improved targets for CRPC that will 
lead to the optimal treatment of men who do progress 
to advanced disease (strategic priority 2). The ration-
ale to invest in research related to strategic priority 1 is 
that an increased accuracy of risk stratification for clini-
cally significant localized disease will support improved 
patient management, including optimized treatment 
decision-making. The rationale for further investment 
into research related to strategic priority 2 is that these 
efforts will eventually optimize the treatment of men 
who do progress to advanced prostate cancer.
These two strategic priorities have been endorsed by 
the Movember Board and Movember is now develop-
ing a range of collaborative research programmes across 
the globe to address these priorities, as well as many of 
the specific key research needs identified during the 
landscape analysis process. To ensure that its research 
investments reflect the needs of men and the research, 
clinical and societal community, Movember will con-
tinue to engage with its patient advocates and global 
thought leaders to maximize outcomes that positively 
change clinical practice and reduce economic burden for 
the benefit of the men that we serve.
Conclusions
To identify the highest priority research needs across the 
prostate cancer biomedical research arena, Movember 
conducted a global landscape analysis. Using extensive 
interviews with men with prostate cancer as well as 
global thought leaders across a range of disciplines, key 
insights were ascertained and 17 critical research needs 
were identified. These research needs were assessed 
and prioritized by an expert LAC and the three highest 
ranked research needs are outlined in detail in this paper. 
The insights garnered from this landscape analysis have 
led Movember to refine its prostate cancer biomedi-
cal research strategic priorities and will inform future 
investments in the global research field with a view to 
maximizing outcomes for men with prostate cancer 
around the world.
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